Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome

In the 2008 study involving 26 women with polycystic ovary syndrome (PCOS), metformin (MET) and rosiglitazone (ROSI) treatments over 6 months were found to significantly improve endothelial function, as indicated by increased flow-mediated dilation (FMD) of the brachial artery. MET treatment also resulted in a significant decrease in insulin resistance, serum total and free testosterone levels, and an increase in menstrual bleeding frequency. The study concluded that MET and ROSI could markedly improve endothelial function in young PCOS patients, potentially reversing early-stage atherosclerotic processes, with MET providing additional benefits in reducing insulin resistance and testosterone levels.